CompletedNot Applicable

Management of Supraventricular Tachycardias in Children

1,400 participantsStarted 2000-01-01

Plain-language summary

Background Supraventricular tachycardias (SVTs) are the most common arrhythmic events in children, with an estimated incidence of 13 per 100,000 per year before the age of 18. Few large patient cohorts have been reported, as most published studies are single-center. Large-scale studies come from medico-administrative databases, which lack the granularity needed for detailed analysis of outcomes according to the therapies used and the type of SVT. Furthermore, although a large proportion of neonatal SVTs do not recur (spontaneous resolution of the accessory pathway), there are limited comparative data on the effectiveness of antiarrhythmic therapies specifically in children after the age of 1 year. Management therefore varies greatly, in part because current guidelines propose different therapeutic options based on low-level evidence. Objectives: * Describe the management of SVTs (antiarrhythmic therapies and catheter ablation) in children in France * Compare the effectiveness of different antiarrhythmic treatments according to age (\<1 year and \>1 year) and type of SVT * Analyze the incidence of adverse events and complications associated with antiarrhythmic treatments and catheter ablation

Who can participate

Age range

0 Years – 18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \<18 years at the time of the first documented supraventricular tachycardia episode Exclusion Criteria: * Early postoperative supraventricular tachycardia (\<30 days) * Age ≥18 years at the first documented supraventricular tachycardia episode * Fetal tachycardias without postnatal recurrence * Atrial extrasystoles without sustained runs (\<30 seconds)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Antiarrhythmic therapies

Timeframe: At the time of the first supraventricular tachycardia recorded

Catheter ablation

Timeframe: At the time of first episode of supraventricular tachycardia or after recurrence

Recurrence of supraventricular tachycardia

Timeframe: At 1 year after antiarrhythmic drug initiation

Trial details

NCT IDNCT07291544

SponsorParis Cardiovascular Research Center (Inserm U970)

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2025-09-30

View on ClinicalTrials.gov More Supraventricular Arrhythmias trials